Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (January 2015)
41 slides from Fluoropharma Medical's investor presentation, Jan 23, 2015
Slide 1: Enabling Personalized Medicine Through Precision Diagnostics
Enabling Personalized Medicine Through Precision Diagnostics (OTCQB:FPMI) Edward L. Lyons Jr. Vice President, Marketing i
Slide 2: Forward-Looking Statements
Forward-Looking Statements. ~ Pharma This presentation contains “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered by th
Slide 3: Patients will die of heart disease
Patients will die of heart disease Acardiac perfusion scan is performed Portfolio of compounds in heart disease duct: BFPET Se CardioPET www. FluoroPharma.com
Slide 4: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance Pharma THE COMPANY CORE EXPERTISE THREE ACTIVE CARDIAC IMAGING PROGRAMS FOR PET IMAGING CLINICAL BENEFITS PATIENT MANAGEMENT * Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital + Next generation molecular imaging drugs for diagnostic test
Slide 5: Cardiovascular Disease is a Major Global Health Burden
Fluorc Cardiovascular Disease is a Major Global Health Burden = Pharma ath ERK KEY FACTS — US AND WW: WHO: “Neglected Global Epidemic" + 16.7 M deaths WW: 1/3 of all deaths, 78% from low / middle income countries. + 4113 of deaths in China, % in Europe + 2.4M deaths US: top cause (38.5%) Blood High
Slide 6: Coronary Disease: Still Driving Cardiovascular Death
Coronary Disease: Still Driving Cardiovascular Death Percentage breakdown of deaths attributable to cardiovascular disease (United States: 2010) oer, 187% American Or Copyright © American Heart Assocation, Inc Al gts reseed. www. FluoroPharma.com GoAetal, Circulation 2014;129:028-0282
Slide 7: Positron Emission Tomography Basics
Positron Emission Tomographi Basic P Pharma Pitnte an itte://en wikipedia ore/wiki/Image:PET-schema,one, Positron Imaging Partners Tanuary 2005 www. FluoroPharma.com
Slide 8: Molecular Imaging Allows 3D Visualization
Molecular Imaging Allows 3D Visual Pharma www. FluoroPharma.com
Slide 9: Molecular Imaging
Molecular Imagi www. FluoroPharma.com
Slide 10: \www.FluoroPharma.com
\www.FluoroPharma.com 2
Slide 11: FluoroPharma Medical Pipeline
FluoroPharma Medic = For use in combination with stress-testing in patients with presumptive chronic CAD = To replace SPECT in Institutions with PET capability = Phase 1 (US) = Phase 2 (US) = U.S. patent through 2025 Perfusion images |= 17 million potential patients | = Detects regions of fatty acid
Slide 12: Coronary Artery Disease Treatment Flow Model
Coronary Artery Disease Treatment Flow Model Pramacciogs | {fra sveas Sect Pex) |__Shect/ PET Point of Service: * Non Hosptal * Hospital Outpatient Femcarine Boon) [Nedeal Treas} + Hospkal Inpatient cratrowston | | "ana Falnese 2, - (west) November, 2011 auc: Th Ayectea Pron Sty Matt Cul, Dee 2008 J
Slide 13: Clinical Pathway for Coronary Angiography or Intervention
ical Pathway for Coronary Angiography or Interventi arma Patients sent for myocardial) perfusion) imaging Inducible ischemia Referral|to) cathetenzauon Retenral to fevascularization’ www. FluoroPharma.com (aerial er a sam eacabes a aa oe eee a
Slide 14: Known or Suspected CAD: Imaging Approaches
Known or Suspected CAD: Dex Pharma Stress/Rest Imaging + Viability Imaging * Stress induced ischemia » Hibernation, Stunning * LV function More invasive www. FluoroPharma.com ‘Adapted from Bax Ji etal. Hoart. 2004;90(Suppl V):v26-v33.
Slide 15: BFPET Clinical Use
Fluorc BFPET Clinical Use - Pharma MYOCARDIAL PERFUSION IMAGING + Evaluate patients with known or suspected CAD + Evaluate CAD in patients that can tolerate exercise as well as pharmacologic stress CURRENT DIAGNOSTIC TEST + Perfusion imaging with SPECT tracers (e.g. T-99m sestamibi,Tc-99m tetrofosmi
Slide 16: BFPET Phase 1 Observations
BFPET Phase 1 Observations ~ Pharma Phase | trial for BFPET (US) demonstrated excellent perfusion imaging properties. Pationts: 12 healthy volunteers ages 20-85 * Noadverse events * No clinically significant changes Noted in followup clinical and laboratory testing = BFPET images have higher resolut
Slide 17: BFPET IIT Study
BFPET IIT Study Pharma www. FluoroPharma.com ‘Source: investigator Initiated Trial; PLA 304, Belling, Chine. ages courtesy of Dr Tien
Slide 18: BFPET images higher resolution than SPECT
Fluoro — — Pharma i BFPET images demonstrated higher resolution than market-standard SPECT on a qualitative basis Tc-99m Sestamibi Standard of Care BFPET On SPECT this patient appeared to ...While BFPET clearly showed that have a defect... this patient's myocardium was www. FluoroPharma.com ‘Soures:
Slide 19: Physicians willing to utilize BFPET once approved
Physicians across the US and EU have expressed a very strong willingness to utilize BFPET once it is approved In blinded research, the product profile for BFPET gained very positive responses from specialists where indicated a willing to increase estimates use after more comfort. Key Takeaways From
Slide 20: Drivers of Referrals to Cardiac PET
Drivers of Referrals to Cardiac PET Drivers and Benefits: Get ioe nano dnd Nata ean 3 ‘© Expansion of clnialIndiealons/eliical needs mori ris nnn twenty i cn lb Lower radiation dose Improved diagnostic accuracy Improved patient outcomes @ continued advancements in scanner technology Fusion of anatom
Slide 21: The BFPET Opportunity: United States
rf Fluoro — The BFPET Opportunity: United States ~ Pharma Market Procedures St PET Market Myocardial perfusion imaging 12 million 5.0 million = Projected BFPET Scans ss, Projected BFPET Revenue mons coy | sBLUOKS wavwFluoroPharma.com Sour: Bick Swan Anais 20:3, Fuorparma Market Model Jan 2015
Slide 22: CardioPET Phase I and II Trials
Normal i Sinect CAD Subject ae Fatty acid analog that detects regions of metabolic insufficiency PHASE | TRIAL COMPLETED (15 NHV and 6 CAD patients) cS * CardioPET promising safety with no AEs detected linical findings consistent with MPI SPECT Infarcted region of the heart * Quality of CardioPET im
Slide 23: CardioPET may provide direction in the diagnosis of ACS
CardioPET may provide direction in the diagnosis of ACS Physicians indicate an unmet need when a patient presents with an equivocal ACS; when the patlent has a “strong story’ of chest pain and shortness of breath but shows up as negative on initial tests. BY [Vil ED Conducts Diagnostic Tests—Patient
Slide 24: Fatty Acid Metabolism of Diabetes and Heart
Fatty Acid Metabolism of Diabetes and Heart harma WELL MRE a www. FluoroPharma.com
Slide 25: Targets Greatest Areas for Cost Reduction
Targets Greatest Areas for Cost Reduction Therapeutics aimed to prevent and best treat disease related to diabetes, obesity and heart disease hold greatest promise Pharmaceuticals enabling personalized, outcomes-driven medicine offer greatest route to reducing the overall costs of healthcare Medical
Slide 26: Phase II CardioPET Data is Emerging
Phase II CardioPET Data is Emerging CardloPET PHASE Il STUDY ‘SAFETY, IMAGE QUALITY AND OPTIMAL Results: image qualtyloptimal timing TIMING FOR MYOCARDIAL IMAGING USING + eset ag tae pnt THE F-18 FATTY ACID ANALOG CaRDIOPET IN pala ac renal KNOWN OR SUSPECTED CAD PATIENTS * eprint s : espe in ne eit
Slide 27: SNMMI Poster on CardioPET Quantitation (1/2)
SNMMI Poster on CardioPET Quantitation (1/2) Fluorg Shanna Ihe | UZ V | LEUVEN Quantification of myocardial perfusion in humans by PET/CT far and the fatty acid analogue ?°F-FCPHA: a feasibility study A 5 eG § von tare nts M.ceeuea? is O.Gheysens 3, Postnow J Nuys K otal Leen Ogi 128, " ns ‘Objectiv
Slide 28: SNMMI Poster on CardioPET Quantitation (2/2)
SNMMI Poster on CardioPET Quantitation (2/2) pHOro Pharma www. FluoroPharma.com J Nucl Med, May 2014; 55: 1770
Slide 29: Coronary Flow Reserve: Clinical Implications
Coronary Flow Reserve: Clinical Implications Current studies conducted with Rubidium-82 & & a & Coronary flow, mL/min per g myocardium 0 2 40 60 80 100 120 140 160 180 ‘Coronary blood pressure, mm Hg ‘Auto-regulation keeps blood flow relatively constant despite coronary pressure; responds to metabol
Slide 30: Preliminary Imaging Performance: PET vs. SPECT
Preliminary Imaging erformance: PET vs. SPECT ae | [| IMAGES THAT TEACH ~ * CardioPET images revealed Anew F-18 labeled PET tracer for fatty acid alterations of fatty acid uptake in — MDs" Manae D Cri M1 Mle ene 904 regions without abnormalities on Dav Vacant MD, 2 aioe Roca MD. Te99m sestamibi SPEC
Slide 31: CardioPET Clinical Use
Fluorc CardioPET Clinical Use - Pharma DIAGNOSIS OF CAD AT REST Evaluate CAD in angina and patients that cannot exercise CARDIAC VIABILITY ASSESSMENT Identify patients that may benefit from PCI or revascularization and guide intervention MYOCARDIAL PERFUSION CURRENT TREATMENT Invasive coronary angio
Slide 32: The CardioPET Opportunity
5. Sie a ool Ze The CardioPET Opportunt i | Pharma Commercial Assumptions Est. PET Market Market Procedures Reeauee CAD diagnosis at rest. © 3.8 million 4 million Cardiac viability i -" Gesement 1.6 million S million Myocardial perfusion imaging 12 million 6 million ‘Courtesy of Fabian Demeure, UCL,
Slide 33: CardioPET (18-F FCPHA)
CardioPET 18-F FCPHA) Pharma luoroPharma.com
Slide 34: Substantial PET Installed Base in the US
Substantial PET Installed Base in the US ~2800 Scanners Operating at ~40% Capacity ~ Pharma Cardiac stress tests are already performed more than 60% of the time at centers with PET machines. ‘The PET machines are currently imaging oncology patients for 95% of their workload Distribution of PET Machi
Slide 35: PET Manufacturing and Distribution
PET Manufacturing and Distribution Pharma Sites where PET products are produced conform to Good Manufacturing Processes (GMP) ‘Administration—Hospttal ‘GMP Manufacturing (Nuclear Medicine/Radiology) Fluorog —_| wo SPharma Well-established infrastructure for cyclotron-produced radiopharmaceuticals. w
Slide 36: harma
harma Approximately 100 FDG production sites (Cardinal Health, IBA, PETNET) will allow FluoroPharma to provide a high level of customer service, enabling product delivery within two to three hours to 85% of PET institutions nationwide. @reAMoieuar © Carnal Hear Qreetn See Onparien 7 repr ahaae/ nae
Slide 37: Paradigm in Healthcare
Paradigm in Healthcare Mecical Groups Medical Groups at scale, true Solo practitioners _(butIndividual preserbers retain coordinated networks and ACOs signfcant autonomy) {ectining preserve autonomy) Quoity patient care = tnococe reputation Moteformal quatymessues, Popul ean outcomes, among patents
Slide 38: Why PET, and Why Now
Why PET, and Why Now: Fluoro —< Quality, infrastructure and increasing installed base ~ Pharma + New care models are driving cost efficiency and outcomes improvement Teictiememisc) | * PET has been shown to have higher rate of specificity and sensitivity than SPECT Geteyieieui | * May provide a more
Slide 39: Experienced Management Team and Advisors
Fluoro — Experienced Management Team and Advisors Pharma This Spoor President, CEO + Healthcare executive with >45 years medical Industry experience + Former securities analyst at JP. Morgan and Credit Sulese covering medical devices and blotochnology + Led the nuclear cardiology portfolio and PET n
Slide 40: Investment Highlights
Investment Highlights - Pharma Radiopharmaceutical company with two next generation cardiovascular imaging agents in Phase 2 + Short Study Timelines/regulatory pathway + Early date demonstrates favorable imaging characteristics + IPis unique in the Molecular Imaging domain ‘+ Intellectual property i
Slide 41: Enabling Personalized Medicine Through Precision Diagnostics
Enabling Personalized Medicine Through Precision Diagnostics (OTCQB:FPMI)
FluoroPharma Medical — Investor Presentation (January 2015) on 6ix